This study is testing a new immunotherapy called anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) for adults with certain types of relapsed or refractory (meaning it came back or didn't respond to previous treatment) CD30-positive blood cancers, including Hodgkin Lymphoma and specific types of T-cell lymphoma. This treatment uses your own T-cells, which are a type of white blood cell, to fight the cancer. You would also receive GM-CSF, a medicine that helps your body make more white blood cells. Researchers want to find the safest dose of CD30 biAb-AATC and see how well it works. The study aims to enroll 42 participants, but its current recruitment status is unclear.

Study design

This is a single-arm, dose-escalating study, meaning all participants receive the same treatment and the dose may increase over time. It is a Phase 1 study, typically involving a small number of participants to assess safety.

What's involved

After T-cells are collected, you may receive chemotherapy for 21 days while your personalized treatment is prepared. You would then receive weekly infusions of CD30 biAb-AATC and twice-weekly GM-CSF injections for up to two 4-week cycles.

Compensation

Not stated in the trial record.

Follow-up

The study will measure the maximum tolerated dose over 2 years, suggesting a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.